Mobile health applications have the potential to significantly change drug development, clinical trials and the administration of health care. In this article, Dr Bill Hanlon, vice president, head of global regulatory affairs at Covance, and Scott Thiel, associated director at Navigant Consulting take a look at the opportunities and challenges of this growing field. Content paid for by Covance.
Two NASH experts discuss critical challenges, biomarkers and insights from scientific and regulatory perspectives. Content paid for by Covance.
With its measurable impact on patient survival, there’s no denying that immunotherapy is already causing momentum in ways that cancer is treated. Drug researchers and developers are identifying new candidates in their growing pipelines and exploring combinations of immunotherapies, while regulatory agencies are providing expedited review and approval of these therapies for new indications at an unprecedented rate.
The pharmaceutical industry continues to strive to improve the quality and efficiency of clinical trials but many challenges remain with these costly and complex operations. One key factor in effectively managing a study from the start requires a realistic estimate of timelines and selection of the most likely investigators and sites to accelerate patient enrollment.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.